Antiangiogenic Compound Axitinib Demonstrates Low Toxicity and Antitumoral Effects against Medulloblastoma
Simple Summary
- Supplementary File 1:
ZIP-Document (ZIP, 2893 KiB)
Pagnuzzi-Boncompagni, M.; Picco, V.; Vial, V.; Planas-Bielsa, V.; Vandenberghe, A.; Daubon, T.; Derieppe, M.-A.; Montemagno, C.; Durivault, J.; Grépin, R.; Martial, S.; Doyen, J.; Gavard, J.; Pagès, G. Antiangiogenic Compound Axitinib Demonstrates Low Toxicity and Antitumoral Effects against Medulloblastoma. Cancers 2022, 14, 70. https://doi.org/10.3390/cancers14010070
Pagnuzzi-Boncompagni M, Picco V, Vial V, Planas-Bielsa V, Vandenberghe A, Daubon T, Derieppe M-A, Montemagno C, Durivault J, Grépin R, Martial S, Doyen J, Gavard J, Pagès G. Antiangiogenic Compound Axitinib Demonstrates Low Toxicity and Antitumoral Effects against Medulloblastoma. Cancers. 2022; 14(1):70. https://doi.org/10.3390/cancers14010070
Chicago/Turabian StylePagnuzzi-Boncompagni, Marina, Vincent Picco, Valérie Vial, Victor Planas-Bielsa, Ashaina Vandenberghe, Thomas Daubon, Marie-Alix Derieppe, Christopher Montemagno, Jérôme Durivault, Renaud Grépin, Sonia Martial, Jérôme Doyen, Julie Gavard, and Gilles Pagès. 2022. "Antiangiogenic Compound Axitinib Demonstrates Low Toxicity and Antitumoral Effects against Medulloblastoma" Cancers 14, no. 1: 70. https://doi.org/10.3390/cancers14010070